EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma

Changyu Yao, Ying Zhou, Liuyang Yu, Li Xu, Shilun Wu, Ruize Gao, Yirui Hou, Wenbing Sun, Jun Gao, Shaohong Wang

Frontiers in Immunology · 2025

DOI: 10.3389/fimmu.2025.1680433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Changyu Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: HMGB1 Protein, Hemangioma, Heme, Systemic Inflammatory Response Syndrome. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although radiofrequency ablation (RFA) is a safe and effective treatment for hepatic hemangiomas, post-RFA systemic inflammatory response syndrome (SIRS) frequently occurs. The role of high-mobility group box 1 (HMGB1) in endothelial cell pyroptosis and SIRS induction following RFA in hepatic hemangiomas remains unexplored.

Methods

In vitro , the levels of interleukin (IL)-1β, IL-18, and pyroptosis markers, such as GSDMD-N and Casp1 p20, were measured in human umbilical vein endothelial cells (HUVECs) after heme administration. In vivo , an orthotopic liver hemangioma mouse model was established, and RFA was performed to evaluate the levels of IL-1β and IL-18, wet-to-dry lung ratio, and inflammation score. In addition, hemopexin and glycyrrhizin were used to investigate the impact of HMGB1 on heme-induced SIRS post-RFA in hepatic hemangioma mice.

Results

Heme induced elevated levels of IL-1β and IL-18, endothelial cell death in vitro , and increased wet-to-dry lung ratio and inflammation score in vivo . These effects were rescued with the administration of heme-binding protein hemopexin, indicating the role of heme in inducing SIRS and pyroptosis post-RFA of hepatic hemangioma. HMGB1 participates in heme-induced SIRS in mice by regulating HMGB1/nod-like receptor family pyrin domain-containing 3 (NLRP3) pathway through reactive oxygen species (ROS). Treatment with hemopexin or the HMGB1 inhibitor glycyrrhizin reversed heme-induced SIRS after RFA of hepatic hemangioma in mice.

Conclusions

Collectively, we demonstrated that heme induces SIRS through the ROS/HMGB1/NLRP3 pathway-regulated endothelial cell pyroptosis in mice, and hemopexin, a heme scavenger, and glycyrrhizin, a HMGB1 inhibitor, may be the potential strategies for further study for SIRS following the RFA of hepatic hemangioma for the first time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinHemangiomaHemeSystemic Inflammatory Response SyndromeLiver NeoplasmsRadiofrequency AblationAnimalsMiceHumansHuman Umbilical Vein Endothelial CellsDisease Models, AnimalPyroptosisMaleHemopexinGlycyrrhizic AcidNLR Family, Pyrin Domain-Containing 3 ProteinMice, Inbred C57BL

Stichwörter der Autor:innen

HMGB1SIRSendothelial cellshemeradiofrequency ablation

Substanzen

HMGB1 ProteinHemeHemopexinGlycyrrhizic AcidNLR Family, Pyrin Domain-Containing 3 ProteinHMGB1 protein, mouse

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
  • Department of Pathology, Peking University People's Hospital, Peking University, Beijing, China.
  • Department of Anesthesiology, Peking University People's Hospital, Peking University, Beijing, China.

Förderung

  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Yao, C., Zhou, Y., Yu, L., Xu, L., Wu, S., Gao, R., Hou, Y., Sun, W., Gao, J., & Wang, S. (2025). Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1680433

Vancouver

Yao C, Zhou Y, Yu L, Xu L, Wu S, Gao R, et al. Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1680433

BibTeX
@article{Yao2025,
  author = {Yao, Changyu and Zhou, Ying and Yu, Liuyang and Xu, Li and Wu, Shilun and Gao, Ruize and Hou, Yirui and Sun, Wenbing and Gao, Jun and Wang, Shaohong},
  title = {Targeting HMGB1 in endothelial cells reverses heme-induced SIRS after radiofrequency ablation of hepatic hemangioma},
  journal = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1680433}
}
Kostenlos starten →